Quoin Pharmaceuticals Receives Patent Allowance for Netherton Syndrome Treatment
Quoin Pharmaceuticals announced that the USPTO has issued a Notice of Allowance for a patent application titled "Combination Treatment for Netherton Syndrome." This patent supports the intellectual property strategy for QRX003, its investigational treatment for Netherton Syndrome, a rare genetic skin disease with no approved treatments. The allowed claims cover a method of treating the condition using a topical serine protease inhibitor and an anti-inflammatory agent, including patients with SPINK5 mutations. This development strengthens the long-term value of the QRX003 program, which has multiple regulatory designations and is progressing towards a potential NDA filing in 2027.
Key Highlights
- USPTO issued Notice of Allowance for U.S. Patent Application No. 18/428,570.
- Patent covers combination treatment for Netherton Syndrome.
- Claims include topical serine protease inhibitor and anti-inflammatory agent.
- Covers treatment for patients with SPINK5 mutations.
- QRX003 holds Orphan Drug, Rare Pediatric Disease, and Fast Track designations.
- QRX003 is in Phase 2 trials; Phase 3 expected in H2 2026.
- Potential NDA filing for QRX003 in 2027.
Price Impact
More from QNRX
Quoin Pharmaceuticals Receives Conditional FDA Approval for QYLEKI Brand Name
Quoin Pharma Establishes Japan Subsidiary for QRX003 Commercialization
Quoin Pharmaceuticals QRX003 Shows Positive Results in Pediatric Netherton Syndrome